MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130.3 USD | +0.05% |
|
+2.20% | +19.53% |
| May. 09 | Merck Says Health Canada Approve Keytruda Combination in Biliary Tract Carcinoma | MT |
| May. 09 | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 64.11B | Sales 2025 * | 68.6B | Capitalization | 330B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.51B | Net income 2025 * | 22.27B | EV / Sales 2024 * | 5.44 x |
| Net Debt 2024 * | 18.91B | Net Debt 2025 * | 7.6B | EV / Sales 2025 * | 4.92 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.6
x | Employees | 71,000 |
| Yield 2024 * |
2.38% | Yield 2025 * |
2.51% | Free-Float | 70.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
| 1 day | +0.29% | ||
| 1 week | +1.54% | ||
| Current month | +0.78% | ||
| 1 month | +2.78% | ||
| 3 months | +3.81% | ||
| 6 months | +27.20% | ||
| Current year | +19.46% |
1 week
126.76
131.51
1 month
124.50132.80
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 0 M€ | +11.39% | - | |
| 5.61% | 0 M€ | +7.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 130.3 | +0.07% | 2 385 309 |
| 24-05-09 | 130.2 | +0.52% | 9,216,740 |
| 24-05-08 | 129.6 | -0.64% | 6,659,121 |
| 24-05-07 | 130.4 | +2.20% | 6,682,316 |
| 24-05-06 | 127.6 | +0.05% | 6,551,962 |
Delayed Quote Nyse, May 09, 2024 at 04:00 pm EDT
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
130.2
USD
Average target price
141.6
USD
Spread / Average Target
+8.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.46% | 330B | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +3.50% | 283B | |
| +16.92% | 239B | |
| +8.06% | 204B | |
| -8.02% | 198B | |
| +8.62% | 168B | |
| +4.43% | 125B |
- Stock Market
- Equities
- MRK Stock